Medivir AB (MVIR) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Medivir AB SEK 1.10, price SEK 1.66, upside -34.1%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medivir AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally.
Show more
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
Stock analysis
Medivir AB (MVIR) currently trades at kr 1.66, while our model-based Fair Value estimate is kr 1.10, implying the stock looks roughly 51.7% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.7565 (bear) to kr 1.44 (bull), the price of kr 1.66 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Medivir AB reported revenue of 8.5M SEK in FY2025 versus 25.5M SEK in FY2021, a compound −24.0%/yr. Reported net income was −94.4M SEK in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 373% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −34%, MVIR screens richer than that median.
Fair Value models
Bear kr 0.7565Fair Value kr 1.10Bull kr 1.44
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+144.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.5%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−252.2% (2021) → −1,093.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside−34% · Above median
Profitability
Return on assets−30% · Bottom 25%
Growth and dividend
Revenue growth83% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.40× · Cheapest 25%
P/S (TTM)11.75× · Priciest 25%
PEG0.74× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medivir AB Fair Value". https://www.fairvalue-calculator.com/stock/MVIR
Frequently asked questions
Is Medivir AB (MVIR) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 1.10 versus a price of kr 1.66, about −34% upside (overvalued).
What is the fair value of MVIR?
Our model-based fair value for Medivir AB is kr 1.10 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 1.66.
What is the quality score of MVIR?
Medivir AB has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medivir AB (MVIR)?
Our model-based price target is the fair value of kr 1.10 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 0.7565, optimistic scenario kr 1.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Medivir AB stock forecast for 2026?
Our models put fair value at kr 1.10, about −34% upside versus a price of kr 1.66 (overvalued). Cautious scenario kr 0.7565, optimistic scenario kr 1.44. The calculation is refreshed regularly with new filings.
What is the revenue of Medivir AB (MVIR)?
Medivir AB reported trailing-twelve-month revenue of about 9.0M SEK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Medivir AB (MVIR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medivir AB it is kr 1.10 per share (as of Sep 24, 2026), against a price of kr 1.66. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Medivir AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MVIR trades above its calculated fair value: price kr 1.66, fair value kr 1.10, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MVIR?
No. The price is what the market pays today (kr 1.66); the fair value is what the company's own numbers justify (kr 1.10). For Medivir AB the two are kr 0.5670 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medivir AB worth?
The market values Medivir AB at about 1.1B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 1.66; our models calculate a fair value of kr 1.10 per share.
What do the bullish and bearish scenarios say about MVIR?
Our models span a range for Medivir AB: cautious scenario kr 0.7565, base kr 1.10, optimistic kr 1.44 per share (as of Sep 24, 2026, price kr 1.66). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MVIR?
The PEG ratio of Medivir AB is 0.74 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Medivir AB (MVIR)?
Balance-sheet figures for Medivir AB (as of Sep 24, 2026): return on equity −61.7%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is MVIR from its 52-week high?
Medivir AB trades at kr 1.66, about 40% below its 52-week high of kr 2.77 and 373% above the low of kr 0.3520 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.10 is for.
Which stocks are comparable to Medivir AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medivir AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 1.66, calculated fair value kr 1.10 (−34%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MVIR calculated?
We run Medivir AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 1.10, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Medivir AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medivir AB (MVIR)?
The closing price on Sep 24, 2026 was kr 1.66. Our model-based fair value is kr 1.10, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medivir AB right now?
The price sits above even our optimistic bull case (kr 1.44). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.7565 to kr 1.44) leaves room in how you read the outcome.
Key figures of Medivir AB
How large is the market capitalisation of Medivir AB (MVIR)?
The market capitalisation of Medivir AB is 1.1B SEK (≈ $106M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Medivir AB (MVIR)?
Earnings per share at Medivir AB are kr −0.5600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Medivir AB (MVIR)?
The return on equity (ROE) of Medivir AB is −61.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medivir AB (MVIR)?
On an EBIT basis the return on assets of Medivir AB is −38.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medivir AB (MVIR)?
The operating margin of Medivir AB is −873% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medivir AB (MVIR)?
Revenue at Medivir AB is growing +83.3% versus a year earlier (3y avg +24.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medivir AB (MVIR) generate?
The free cash flow of Medivir AB is −73.3M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Medivir AB in the live analysis
One click puts Medivir AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
